Clinical evaluation reports safety and effectiveness of isavuconazole in non-neutropenic patients, highlighting utility in invasive fungal infections.
Information is scarce on clinical experiences with non-neutropenic patients with invasive fungal infection (IFI) receiving isavuconazole. We aimed to report the safety and effectiveness of this drug as a first-line treatment or rescue in real life.
No takes yet. Share an insight, caveat, or question.
Monzó et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: